Brugnolo F - Search Results

1

Partial safety of the new COX-2 inhibitor rofecoxib in NSAIDs high sensitive patients.

Matucci A, Parronchi P, Vultaggio A, Rossi O, Brugnolo F, Maggi E, Romagnani S. Matucci A, et al. Among authors: brugnolo f. Allergy. 2004 Oct;59(10):1133-4. doi: 10.1111/j.1398-9995.2004.00532.x. Allergy. 2004. PMID: 15355480 No abstract available.

2

Coronary vasospasm during an acute allergic reaction.

Matucci, Rossi O, Cecchi L, Vultaggio A, Parronchi P, Brugnolo F, Maggi E, Romagnani S. Matucci, et al. Among authors: brugnolo f. Allergy. 2002 Sep;57(9):867-8. doi: 10.1034/j.1398-9995.2002.23575_11.x. Allergy. 2002. PMID: 12169196 No abstract available.

3

The novel synthetic immune response modifier R-848 (Resiquimod) shifts human allergen-specific CD4+ TH2 lymphocytes into IFN-gamma-producing cells.

Brugnolo F, Sampognaro S, Liotta F, Cosmi L, Annunziato F, Manuelli C, Campi P, Maggi E, Romagnani S, Parronchi P. Brugnolo F, et al. J Allergy Clin Immunol. 2003 Feb;111(2):380-8. doi: 10.1067/mai.2003.102. J Allergy Clin Immunol. 2003. PMID: 12589360

4

Genetic and environmental factors contributing to the onset of allergic disorders.

Parronchi P, Brugnolo F, Sampognaro S, Maggi E. Parronchi P, et al. Among authors: brugnolo f. Int Arch Allergy Immunol. 2000 Jan;121(1):2-9. doi: 10.1159/000024291. Int Arch Allergy Immunol. 2000. PMID: 10686503 Review.

5

Reversal of human allergen-specific CRTH2+ T(H)2 cells by IL-12 or the PS-DSP30 oligodeoxynucleotide.

Annunziato F, Cosmi L, Manetti R, Brugnolo F, Parronchi P, Maggi E, Nagata K, Romagnani S. Annunziato F, et al. Among authors: brugnolo f. J Allergy Clin Immunol. 2001 Nov;108(5):815-21. doi: 10.1067/mai.2001.119156. J Allergy Clin Immunol. 2001. PMID: 11692110

6

Highly Th2-skewed cytokine profile of beta-lactam-specific T cells from nonatopic subjects with adverse drug reactions.

Brugnolo F, Annunziato F, Sampognaro S, Campi P, Manfredi M, Matucci A, Blanca M, Romagnani S, Maggi E, Parronchi P. Brugnolo F, et al. J Immunol. 1999 Jul 15;163(2):1053-9. J Immunol. 1999. PMID: 10395704

7

Phosphorothioate oligodeoxynucleotides promote the in vitro development of human allergen-specific CD4+ T cells into Th1 effectors.

Parronchi P, Brugnolo F, Annunziato F, Manuelli C, Sampognaro S, Mavilia C, Romagnani S, Maggi E. Parronchi P, et al. Among authors: brugnolo f. J Immunol. 1999 Dec 1;163(11):5946-53. J Immunol. 1999. PMID: 10570281

8

Phosphorothioate oligonucleotides: looking for the motif(s) possessing immunostimulatory activities in humans.

Brugnolo F, Annunziato F, Sampognaro S, Manuelli C, Cosmi L, Romagnani S, Maggi E, Parronchi P. Brugnolo F, et al. Adv Exp Med Biol. 2001;495:261-4. doi: 10.1007/978-1-4615-0685-0_35. Adv Exp Med Biol. 2001. PMID: 11774576 No abstract available.

9

Influence of both TCR repertoire and severity of the atopic status on the cytokine secretion profile of Parietaria officinalis-specific T cells.

Parronchi P, Sampognaro S, Annunziato F, Brugnolo F, Radbruch A, Di Modugno F, Ruffilli A, Romagnani S, Maggi E. Parronchi P, et al. Among authors: brugnolo f. Eur J Immunol. 1998 Jan;28(1):37-46. doi: 10.1002/(SICI)1521-4141(199801)28:01<37::AID-IMMU37>3.0.CO;2-C. Eur J Immunol. 1998. PMID: 9485184 Free article.

10

Long term efficacy of high-dose intravenous methylprednisolone pulses in active lupus nephritis. A 21-month prospective study.

Bertoni M, Brugnolo F, Bertoni E, Salvadori M, Romagnani S, Emmi L. Bertoni M, et al. Among authors: brugnolo f. Scand J Rheumatol. 1994;23(2):82-6. doi: 10.3109/03009749409103033. Scand J Rheumatol. 1994. PMID: 8165443

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

23 results

Search Page

Filters